首页> 外文期刊>Nature >The Shigellaflexneri effector OspI deamidates UBC13 to dampen the inflammatory response
【24h】

The Shigellaflexneri effector OspI deamidates UBC13 to dampen the inflammatory response

机译:Shifellaflexneri效应蛋白OspI使UBC13脱酰胺化以减弱炎症反应

获取原文
获取原文并翻译 | 示例
       

摘要

Many bacterial pathogens can enter various host cells and then survive intracellularly, transiently evade humoral immunity, and further disseminate to other cells and tissues. When bacteria enter host cells and replicate intracellularly, the host cells sense the invading bacteria as damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs) by way of various pattern recognition receptors. As a result, the host cells induce alarm signals that activate the innate immune system. Therefore, bacteria must modulate host inflammatory signalling and dampen these alarm signals. How pathogens do this after invading epithelial cells remains unclear, however. Here we show that Ospl, a Shigella flexneri effector encoded by ORF169b on the large plasmid and delivered by the type Ⅲ secretion system, dampens acute inflammatory responses during bacterial invasion by suppressing the tumour-necrosis factor (TNF)-receptor-associated factor 6 (TRAF6)-mediated signalling pathway. Ospl is a glutamine deamidase that selectively deamidates the glutamine residue at position 100 in UBC13 to a glutamic acid residue. Consequently, the E2 ubiquitin-conjugating activity required for TRAF6 activation is inhibited, allowing S. flexneri Ospl to modulate the diacylglycerol-CBM (CARD-BCL10-MALT1) complex-TRAF6-nudear-factor-κB signalling pathway. We determined the 2.0 A crystal structure of Ospl, which contains a putative cysteine-histidine-aspartic acid catalytic triad. A mutational analysis showed this catalytic triad to be essential for the deamidation of UBC13. Our results suggest that S. flexneri inhibits acute inflammatory responses in the initial stage of infection by targeting the UBC13-TRAF6 complex.
机译:许多细菌性病原体可以进入各种宿主细胞,然后在细胞内存活,暂时逃避体液免疫,并进一步传播到其他细胞和组织。当细菌进入宿主细胞并在细胞内复制时,宿主细胞通过各种模式识别受体将入侵的细菌感知为损伤相关分子模式(DAMP)和病原体相关分子模式(PAMP)。结果,宿主细胞诱导出警报信号,从而激活先天免疫系统。因此,细菌必须调节宿主的炎症信号并减弱这些警报信号。但是,病原体侵袭上皮细胞后如何做到这一点仍不清楚。在这里,我们显示Ospl是由大型质粒上的ORF169b编码并由Ⅲ型分泌系统传递的弗氏志贺氏菌(Shigella flexneri)效应子,它通过抑制肿瘤坏死因子(TNF)受体相关因子6( TRAF6)介导的信号通路。 Ospl是一种谷氨酰胺脱酰胺酶,其将UBC13中第100位的谷氨酰胺残基选择性地脱氨成谷氨酸残基。因此,TRAF6激活所需的E2泛素结合活性受到抑制,从而使弗氏链球菌Ospl可以调节二酰基甘油-CBM(CARD-BCL10-MALT1)复合物-TRAF6-核因子-κB信号通路。我们确定了Ospl的2.0 A晶体结构,其中包含推定的半胱氨酸-组氨酸-天冬氨酸催化三联体。突变分析表明,该催化三联体对于UBC13的脱酰胺作用至关重要。我们的结果表明,弗氏链球菌通过靶向UBC13-TRAF6复合体,在感染的初始阶段抑制了急性炎症反应。

著录项

  • 来源
    《Nature》 |2012年第7391期|p.623-626|共4页
  • 作者单位

    Departmentof Infectious Disease Control, International Research Centerfor Infectious Diseases, University of Tokyo, Minato-ku, Tokyo 108-8639 Japan;

    Departmentof Infectious Disease Control, International Research Centerfor Infectious Diseases, University of Tokyo, Minato-ku, Tokyo 108-8639 Japan;

    Division of Bacteriology, Department of Infectious Disease Control, International Research Center for infectious Diseases, University of Tokyo, Minato-ku, Tokyo 108-8639, Japan;

    Division of Bacterial Infection, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo,Minato-kuJokyo 108-8639, Japan;

    Division of Bacterial Infection, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo,Minato-kuJokyo 108-8639, Japan;

    Division of Bacterial Infection, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo,Minato-kuJokyo 108-8639, Japan;

    Division of Bacterial Infection, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo,Minato-kuJokyo 108-8639, Japan;

    Division of Bacterial Infection, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo,Minato-kuJokyo 108-8639, Japan;

    Nippon Institute for Biological Science, 9-2221-1 Shinmachi,Ome,Tokyo 198-0024, Japan;

    Nippon Institute for Biological Science, 9-2221-1 Shinmachi,Ome,Tokyo 198-0024, Japan;

    Division of Cellular and Moiecular Biology, Department of Cancer Biology, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo 108-8639, Japan;

    Division of Cellular and Moiecular Biology, Department of Cancer Biology, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo 108-8639, Japan;

    Division of Cellular and Moiecular Biology, Department of Cancer Biology, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo 108-8639, Japan;

    Picobiology Institute, Department of Life Science, Graduate School of Life Science, University of Hyogo, 3-2-1 Kouto, Kamigori, Akoh, Hyogo 678-1297, Japan;

    Departmentof Infectious Disease Control, International Research Centerfor Infectious Diseases, University of Tokyo, Minato-ku, Tokyo 108-8639 Japan,Division of Bacterial Infection, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo,Minato-kuJokyo 108-8639, Japan,Nippon Institute for Biological Science, 9-2221-1 Shinmachi,Ome,Tokyo 198-0024, Japan;

  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-18 02:54:06

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号